<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        
        
        
        <link rel="shortcut icon" href="../../img/favicon.ico">
        <title>Immunotherapy related Endocrinopathies - MediWiki</title>
        <link href="../../css/bootstrap.min.css" rel="stylesheet">
        <link href="../../css/font-awesome.min.css" rel="stylesheet">
        <link href="../../css/base.css" rel="stylesheet">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/styles/color-brewer.min.css">
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/highlight.min.js"></script>
        <script>hljs.highlightAll();</script> 
    </head>

    <body>
        <div class="navbar fixed-top navbar-expand-lg navbar-dark bg-primary">
            <div class="container">
                <a class="navbar-brand" href="../..">MediWiki</a>
                <!-- Expander button -->
                <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#navbar-collapse">
                    <span class="navbar-toggler-icon"></span>
                </button>

                <!-- Expanded navigation -->
                <div id="navbar-collapse" class="navbar-collapse collapse">
                        <!-- Main navigation -->
                        <ul class="nav navbar-nav">
                            <li class="navitem">
                                <a href="../../Basic%20Clinical%20Sciences.html" class="nav-link">Basic Clinical Sciences</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Internal%20Medicine.html" class="nav-link">Internal Medicine</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Surgery.html" class="nav-link">Surgery</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Psychiatry.html" class="nav-link">Psychiatry</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Critical%20Care.html" class="nav-link">Critical Care</a>
                            </li>
                        </ul>

                    <ul class="nav navbar-nav ml-auto">
                        <li class="nav-item">
                            <a href="#" class="nav-link" data-toggle="modal" data-target="#mkdocs_search_modal">
                                <i class="fa fa-search"></i> Search
                            </a>
                        </li>
                            <li class="nav-item">
                                <a rel="prev" href="Hypopituitarism.html" class="nav-link">
                                    <i class="fa fa-arrow-left"></i> Previous
                                </a>
                            </li>
                            <li class="nav-item">
                                <a rel="next" href="Insulin%20switch%20between%20basal-bolus%20and%20premixed.html" class="nav-link">
                                    Next <i class="fa fa-arrow-right"></i>
                                </a>
                            </li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="container">
            <div class="row">
                    <div class="col-md-3"><div class="navbar-light navbar-expand-md bs-sidebar hidden-print affix" role="complementary">
    <div class="navbar-header">
        <button type="button" class="navbar-toggler collapsed" data-toggle="collapse" data-target="#toc-collapse" title="Table of Contents">
            <span class="fa fa-angle-down"></span>
        </button>
    </div>

    
    <div id="toc-collapse" class="navbar-collapse collapse card bg-secondary">
        <ul class="nav flex-column">
            
            <li class="nav-item" data-level="1"><a href="#immunotherapy-related-endocrinopathies" class="nav-link">Immunotherapy related Endocrinopathies</a>
              <ul class="nav flex-column">
            <li class="nav-item" data-level="2"><a href="#immune-checkpoint-inhibitors" class="nav-link">Immune checkpoint inhibitors</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#immune-related-adverse-events" class="nav-link">Immune related adverse events</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#general-approach-to-iraes" class="nav-link">General approach to IRAEs</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#pituitary-irae" class="nav-link">Pituitary IRAE</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-acth-phenotype-hypophysitis" class="nav-link">IRAE: ACTH phenotype hypophysitis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-tsh-deficiency-hypophysitis" class="nav-link">IRAE: TSH deficiency hypophysitis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#prognosis_1" class="nav-link">Prognosis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-central-hypogonadism-lhfsh-low-hypophysitis" class="nav-link">IRAE: Central hypogonadism (LH/FSH low) hypophysitis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-gh-deficiency-hypophysitis" class="nav-link">IRAE: GH deficiency hypophysitis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-adh-deficiency-diabetes-insipidus-hypophysitis" class="nav-link">IRAE: ADH deficiency (Diabetes insipidus) hypophysitis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-thyroid-related-iraes" class="nav-link">IRAE: Thyroid related IRAEs</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-pancreas-related-iraes" class="nav-link">IRAE: Pancreas related IRAEs</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-adrenal-related-iraes" class="nav-link">IRAE: Adrenal related IRAEs</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#irae-parathyroid-related-iraes" class="nav-link">IRAE: Parathyroid related IRAEs</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#diagnosis_3" class="nav-link">Diagnosis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
              </ul>
            </li>
        </ul>
    </div>
</div></div>
                    <div class="col-md-9" role="main">

<h1 id="immunotherapy-related-endocrinopathies">Immunotherapy related Endocrinopathies</h1>
<p>RACP dotpoint</p>
<ul>
<li>Broad pharmacological principles and complications of chemotherapy, endocrine therapy, immunotherapy, molecular targed therapy and radiotherapy</li>
</ul>
<h2 id="immune-checkpoint-inhibitors">Immune checkpoint inhibitors</h2>
<ul>
<li>Removes break on immune system<ul>
<li>allows immune recognition and destruction of cancer cells</li>
<li>also result in self-targets (off target immune responses)</li>
</ul>
</li>
<li>monoclonal antibodies targeting specific cell surface molecules which act as checkpoints on the immune system<ul>
<li>Anti-CTLA4 - ipilimumab</li>
<li>Anti-PD1 - nivolumab, pembrolizumab, cemiplimab</li>
<li>Anti-PDL1 - atezolizumab, avelumab, durvalumab</li>
</ul>
</li>
</ul>
<p><img alt="" src="../../figures/Pasted%20image%2020231106124127.png" /></p>
<h2 id="immune-related-adverse-events">Immune related adverse events</h2>
<ul>
<li>endocrine events most common<ul>
<li>10-20%</li>
<li>median onset 8 weeks post initiation</li>
<li>most commonly pituitary, thyroid, less commonly adrenals, pancreas, parathyroid</li>
</ul>
</li>
<li>immunologic response tends to result in irreversible endocrine dysfunction and destruction of tissues<ul>
<li>irreverisble hypotension</li>
<li>however the greater the IRAE, the greater the oncological response</li>
</ul>
</li>
</ul>
<p><img alt="" src="../../figures/Pasted%20image%2020231106124447.png" />
- overall survival in melanoma treatment vs. experience of endocrine events</p>
<h2 id="general-approach-to-iraes">General approach to IRAEs</h2>
<ul>
<li>Typically nonspecific presentations or asymptomatic<ul>
<li>potentially fatal - <strong>particularly hypocorticolism</strong></li>
<li>routine monitoring needed through biochemical testing</li>
</ul>
</li>
<li>European society 2022 guidelines<ul>
<li>minimum - prior to each endocrine cycle<ul>
<li>8-9am serum cortisol, TSH, fT4, glucose, EUCs</li>
</ul>
</li>
<li>high risk scenarios<ul>
<li>ACTH, LH, FSH, E2/testosterone, prolactin (e.g. if on ipilimumab)</li>
<li>HbA1c (e.g. if suspected pre-existing T2DM and need to assess for development of autoimmune diabetes</li>
</ul>
</li>
<li>Diagnostic testing PRN and screen for other endocrinopathies if concerned </li>
<li>existing endocrinopathy is NOT a contraindication for ICI initiation/continuation<ul>
<li>no additinoal risk of adverse events</li>
<li>cancer benefit significantly outweighs endocrinopathy</li>
<li>Endocrine emergencies (e.g. DKA, adrenal crisis, severe thyrotoxicosis, severe grave's opthalmopathy) MUST be treated prior to next cycle</li>
<li>high dose steroids is rarely indicated - no evidence that it affects permanent hormone deficiencies</li>
<li>endocrinologist should be involved unless isolated primary hypothyroidism<ul>
<li>may be permanent and co-exist</li>
<li>risk of long term complications</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="pituitary-irae">Pituitary IRAE</h2>
<ul>
<li>Hypophysitis related to immunotherapy<ul>
<li>RF: Male, Older age, Ipilimumab if &gt;3mg/kg</li>
<li>typically ACTH deficiency (vs nonimmune mediated hypophysitis where you see hyperprolactinaemia or DI)</li>
<li>positive pitutiary antibodies found when tested in literature<ul>
<li>however not commonly available</li>
</ul>
</li>
<li>diagnosed off<ul>
<li>full pitutitary panel</li>
<li>pituitary MRI - mainly to exclude pituitary metastasis
<img alt="" src="../../figures/Pasted%20image%2020231106125212.png" /></li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Two main phenotypes
<img alt="" src="../../figures/Pasted%20image%2020231106125149.png" /></p>
<h2 id="irae-acth-phenotype-hypophysitis">IRAE: ACTH phenotype hypophysitis</h2>
<h3 id="clinical-presentation">Clinical presentation</h3>
<ul>
<li>Adrenal crisis</li>
</ul>
<h3 id="diagnosis-and-management">Diagnosis and management</h3>
<ul>
<li>Take blood for cortisol and ACTH → send on ice</li>
<li>do not wait for results<ul>
<li>Give hydrocortisone 100mg IV/IM → 50mg q6hrly + IVF resuscitation</li>
<li>maintenance therapy<ul>
<li>hydrocoritsone 15-25mg split doses → monitor clinically (no role for cortisol monitoring)</li>
<li>educate RE sick day rules, steroid emergency card, MedicAlert bracelet, taught to monitor Solu-Cortef</li>
<li>no mineralocorticoid requirement in secondary adrenal insufficiency - aldosterone is produced by RAAS rather than ACTH<ul>
<li>Addison's → needs hydrocortisone AND fludrocortisone</li>
<li>Central → needs hydrocortisone only</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>NO role for supraphysiological steroids unless visual loss due to suprachiasmal compression or intractible headaches<ul>
<li>even in these cases, would be questionable</li>
</ul>
</li>
</ul>
<h3 id="prognosis">Prognosis</h3>
<ul>
<li>ACTH recovery rare → will likely need lifelong treatment</li>
</ul>
<h2 id="irae-tsh-deficiency-hypophysitis">IRAE: TSH deficiency hypophysitis</h2>
<h3 id="diagnosis">Diagnosis</h3>
<ul>
<li>Low-normal fT3 and inappropriately normal/low TSH<ul>
<li>may be heralded by TSH drop - &gt;80% drop in TSH resulted in ipilimumab induced hypophysitis in Australian study</li>
</ul>
</li>
</ul>
<h3 id="management">Management</h3>
<ul>
<li>Thyroxine 1mcg/kg (25-50 mcg if elderly/cardiac disease)</li>
<li>repeat TFTs 6 weekly → aim fT4 upper half of normal range</li>
</ul>
<h2 id="prognosis_1">Prognosis</h2>
<ul>
<li>TSH recovery infrequent</li>
<li>consider tapering and trialling off thyroxine if low requirements</li>
</ul>
<h2 id="irae-central-hypogonadism-lhfsh-low-hypophysitis">IRAE: Central hypogonadism (LH/FSH low) hypophysitis</h2>
<h3 id="management_1">Management</h3>
<ul>
<li>Depends on oncological prognosis<ul>
<li>If poor oncological prognosis:<ul>
<li>do NOT replace LH/FSH - suppression may be physiological with minimal benefit - especially if older</li>
<li>deficiency may be reversible </li>
</ul>
</li>
<li>If good oncological prognosis without contraindications to sex hormone therapy (e.g. breast, prostate, ovarian)<ul>
<li>Testosterone for men</li>
<li>Oestrogen for reproducitve age women<ul>
<li>progestin for in-tact uterus for endometrial protection</li>
</ul>
</li>
</ul>
</li>
<li>consider preventative management<ul>
<li>Calcium/vitamin D as needed</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="irae-gh-deficiency-hypophysitis">IRAE: GH deficiency hypophysitis</h2>
<h3 id="management_2">Management</h3>
<ul>
<li>probably underestimated, but do not look for this in a clinical or academic setting </li>
</ul>
<h2 id="irae-adh-deficiency-diabetes-insipidus-hypophysitis">IRAE: ADH deficiency (Diabetes insipidus) hypophysitis</h2>
<h3 id="general-features">General features</h3>
<ul>
<li>Diabetes insipidus rare</li>
</ul>
<h3 id="diagnosis_1">Diagnosis</h3>
<ul>
<li>Poluria &gt;50mL/kg/day</li>
<li>serum osmolality &gt; 295mOsm/kg + urine Osm:serum Osm &lt; 2</li>
<li>Consider other causes of polyuria - hyperglycaemia, diuretics, renal dysfunction, hypokalaemia, hypercalcaemia</li>
<li>if cannot diagnose on baseline testing, consider <ul>
<li>stimulated copeptin (e.g. hypertonic saline)</li>
<li>desmopressin stimulation test - 1mcg IV/SC = 10mcg intranasal = 200mcg PO</li>
</ul>
</li>
</ul>
<h2 id="irae-thyroid-related-iraes">IRAE: Thyroid related IRAEs</h2>
<h3 id="general-features_1">General features</h3>
<ul>
<li>Most common ICI-induced endocrinopathy, especially associated with anti-PD1 inhibitors<ul>
<li>maybe due to PD1-R on thyrocytes
<img alt="" src="../../figures/Pasted%20image%2020231106131112.png" /></li>
</ul>
</li>
</ul>
<h3 id="clinical-presentation_1">Clinical presentation</h3>
<ul>
<li>transient thyrotoxicosis within 6wks of ICI initiation → hypothyroidism after another 6 weeks</li>
<li>typically destructive thyroiditis - rarely Graves' disease +/- ophthalmopathy<ul>
<li>thyrotoxic phase generally asymptomatic and resolves spontaneously</li>
<li>hypothyroidism usually irreversible</li>
</ul>
</li>
<li>no reliable predictive factors for risk/pattern</li>
</ul>
<h3 id="diagnosis-and-management_1">Diagnosis and management</h3>
<ul>
<li>TSH + fT4<ul>
<li>consider confounders - drugs, nonthyroidal illness, iodine loads</li>
</ul>
</li>
<li>Primary hypothyroidism → Anti-TPO<ul>
<li>thyroxine if low fT4 + TSH &gt; 10mIU/L - if above this, then possible confounding - hold off treatment til diagnosis confirmed</li>
<li>Same dose as for central hypothyroidism:<ul>
<li>1mcg/kg starting dose → TFTs 6 wks later, consider trial off thyroxine if low requirements</li>
<li>target normal tSH</li>
</ul>
</li>
</ul>
</li>
<li>thyrotoxicosis → TSH receptor antibody<ul>
<li>negative → thyroiditis<ul>
<li>if cannot manage medically, may need beta blockers for symptomatic relief</li>
</ul>
</li>
<li>positive → Graves' disease<ul>
<li>thionamides (carbimazole, PTU) - used for treatment of <strong>immunotherapy related Graves' disease</strong></li>
<li>rarely consider TRAb-negative Graves' disease if prolonged thyrotoxicosis, hypervascular goitre (thrill/bruit on examination) or ophthalmopathy (look for disproportionate fT3 vs. fT4, thyroid scintigraphy/US hypervascularity)</li>
</ul>
</li>
</ul>
</li>
<li>Generally no role for high dose steroids except possibly in severe thyrotoxicosis<ul>
<li>used for reduced converstion of T4 to T3 and ophthalmopathy (for antiinflammatory effect)</li>
</ul>
</li>
</ul>
<h2 id="irae-pancreas-related-iraes">IRAE: Pancreas related IRAEs</h2>
<h3 id="general-faetures">General faetures</h3>
<ul>
<li>Autoimmune diabetes is rare - 1-2% incidence</li>
<li>Risk factors - Male, older age<ul>
<li>Anti PD1 &gt;&gt;&gt; Anti-PDL1 &gt; Anti-CTLA4</li>
</ul>
</li>
<li>Differentials<ul>
<li>T2Dm, glucocorticoid-induced hyperglycaemia, pancreatogenic diabetes</li>
</ul>
</li>
</ul>
<h3 id="management_3">Management</h3>
<ul>
<li>Hyperglycaemia → Test for T1DM antibodies (anti-GAD, Anti-IR2)<ul>
<li>not frequently negative → does not exclude autoimmune diabetes</li>
<li>expect an inappropriately low C-peptide level for glucose level (inadequate insulin production, IDDM)</li>
<li>ketones and blood pH - tend to present with DKA<ul>
<li>may need fluid resuscitation, etc </li>
</ul>
</li>
</ul>
</li>
<li>no benefit from high dose steroids - will almost certainly worsen hyperglycaemia</li>
<li>Teach how to use GlucaGen HypoKit due to <strong>similar rates of hypoglycaemia to T1DM</strong></li>
</ul>
<h3 id="prognosis_2">Prognosis</h3>
<ul>
<li>virtually always permanent</li>
<li>risk of DKA if insulin withdrawn</li>
</ul>
<h2 id="irae-adrenal-related-iraes">IRAE: Adrenal related IRAEs</h2>
<h3 id="general-features_2">General Features</h3>
<ul>
<li>Primary adrenal insufficiency very rare<ul>
<li>45 definite cases in WHO VigiBase</li>
</ul>
</li>
<li>typically follows Anti-PD1/PDL1 use and has coexisting autoimmune disease</li>
</ul>
<h3 id="diagnosis_2">Diagnosis</h3>
<ul>
<li>low AM cortisol and ACTH &gt;2fold normal</li>
<li>may need short synacthen test</li>
<li>21-OHase antibody is sometimes positive + All patients - CT adrenals to exclude metastases<ul>
<li>differs from addison's disease outside cancer setting where 21-OHase antibody positivity defines addison's disease and CT only for negative natibody to identify infiltrative disease</li>
</ul>
</li>
</ul>
<h3 id="management_4">Management</h3>
<ul>
<li>Treat as other cases of primary adrenal insufficiency<ul>
<li>Hydrocortisone 15-25mg split BD/TDS</li>
<li>Fludrocortisone 50-150mcg mane</li>
<li>liberal salt intake</li>
<li>self management strategies as for central hypocortisolism</li>
</ul>
</li>
<li>no role for high dose corticosteroids apart from full physiological replacement in adrenal crisis<ul>
<li>up to 200mg hydrocortisone a day - no need for higher</li>
</ul>
</li>
</ul>
<h3 id="prognosis_3">Prognosis</h3>
<ul>
<li>recovery not reported to date - may need indefinitely</li>
</ul>
<h2 id="irae-parathyroid-related-iraes">IRAE: Parathyroid related IRAEs</h2>
<h3 id="general-features_3">General features</h3>
<ul>
<li>primary hypoparathyroidism exceedingly rare - 6 cases reported so far</li>
</ul>
<h2 id="diagnosis_3">Diagnosis</h2>
<ul>
<li>symptomatic hypocalcaemia - fatigue, weakness, paraesthesia, GI upset</li>
<li>serum calcium 1.25-1.63mmol/L</li>
<li>undetectable or low-normal PTH</li>
<li>activating CaSR autoantibodies in 3 cases - not available clinically</li>
<li>permanent calcium requirement in each of the 6 cases reported</li>
<li>Cosnider differentials<ul>
<li>Hypocalcaemia → PO4, Mg, VitD, PTH (note CaSR Ab testing not available)</li>
</ul>
</li>
</ul>
<h3 id="management_5">Management</h3>
<ul>
<li>IV/PO calcium - depends on degree of hypocalcaemia</li>
<li>Calcitriol</li>
<li>Correct hypomagnesaemia </li>
</ul></div>
            </div>
        </div>

        <footer class="col-md-12">
            <hr>
                <p>Copyright &copy; 2021 Weber Liu</p>
            <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a>.</p>
        </footer>
        <script src="../../js/jquery-3.6.0.min.js"></script>
        <script src="../../js/bootstrap.min.js"></script>
        <script>
            var base_url = "../..",
                shortcuts = {"help": 191, "next": 78, "previous": 80, "search": 83};
        </script>
        <script src="../../js/base.js"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="../../search/main.js"></script>

        <div class="modal" id="mkdocs_search_modal" tabindex="-1" role="dialog" aria-labelledby="searchModalLabel" aria-hidden="true">
    <div class="modal-dialog modal-lg">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="searchModalLabel">Search</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
                <p>From here you can search these documents. Enter your search terms below.</p>
                <form>
                    <div class="form-group">
                        <input type="search" class="form-control" placeholder="Search..." id="mkdocs-search-query" title="Type search term here">
                    </div>
                </form>
                <div id="mkdocs-search-results" data-no-results-text="No results found"></div>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div><div class="modal" id="mkdocs_keyboard_modal" tabindex="-1" role="dialog" aria-labelledby="keyboardModalLabel" aria-hidden="true">
    <div class="modal-dialog">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="keyboardModalLabel">Keyboard Shortcuts</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
              <table class="table">
                <thead>
                  <tr>
                    <th style="width: 20%;">Keys</th>
                    <th>Action</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="help shortcut"><kbd>?</kbd></td>
                    <td>Open this help</td>
                  </tr>
                  <tr>
                    <td class="next shortcut"><kbd>n</kbd></td>
                    <td>Next page</td>
                  </tr>
                  <tr>
                    <td class="prev shortcut"><kbd>p</kbd></td>
                    <td>Previous page</td>
                  </tr>
                  <tr>
                    <td class="search shortcut"><kbd>s</kbd></td>
                    <td>Search</td>
                  </tr>
                </tbody>
              </table>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div>

    </body>
</html>
